Interviews

Joe O'Sullivan, MD, on utilizing radium-223 treatment earlier in patients with metastatic castration-resistant prostate cancer (mCRPC).

Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.

Tamar Safra, MD, talks about research into treatments for specific types of ovarian cancer.

Michael Birrer, MD, PhD, on treatments targeting either VEGF or ANG2 in gynecologic cancers.

Thomas Herzog, MD, on the cautions of interval debulking surgery in ovarian cancer and its difference from neoadjuvant treatment. Herzog said interval debulking surgery entails an initial, maximum surgical effort that is followed up by chemotherapy.

Philip Philip, MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, on treatment options for patients with advanced pancreatic cancer.

Dr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).

Mark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.

Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.

Howard A. "Skip" Burris, III, MD, president, Clinical Operations, chief medical officer and executive director of Drug Development, Sarah Cannon, talks about chemotherapy in the era of personalized medicine.

R. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer.

Mohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab.

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.

Patrick Borgen, MD, says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.

Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.

Aaron Spitz, MD, talks about the emerging uses of telemedicine in urology. Telemedicine allows medical professionals to remotely diagnose and sometimes even treat patients through a variety of technology, including smartphones and tablet devices.

Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium. 

John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.

Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.

Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.

Dr. Judy C. Boughey talks about a study examining all patients at Mayo Clinic that underwent a nipple-sparing mastectomy for breast cancer and comparing those with positive lymph nodes to those with negative lymph nodes.

Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.

Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.

Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.

Christiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.

Mayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).

Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.

Frank A. Sinicrope, MD, talks about sporadic mismatch repair deficient colonic cancer tumors compared to familial related to germ line mutations in the setting of Lynch syndrome.

Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.